Turkey first domestically-developed the Turkovac coronavirus vaccine took another cue step. The Ministry of Health announced Tuesday that the blow would be the country first vaccine to be used abroad in its clinical trials in Azerbaijan. Trials of phase III of the vaccine, which received emergency approval in Turkey sooner, will available for citizens of Azerbaijan as a third dose of the vaccine as part of of his trials. Any citizen of the country, which is one of Turkey’s closest allies, who received two doses of another inactive vaccine, will be eligible to participate in the trial.
The ministry said in a statement that the trial will proceed in Cooperation with Baku Health Center Hospital in Azerbaijan in the Azerbaijani capital and the presidency of Health institutes of Turkey (TÜSEB), the main sponsor of from Turkovac development by a group of scientists from the University of Erciyes. A delegation from TÜSEB, including its director professor Erhan Akdogan, professor Ates Kara, who lead turkey main vaccine institute and is a member of the Scientific Advisory Board on Coronavirus of the Ministry of Health, were to travel to Baku to sign a protocol for trials on Wednesday.
The statement also said efforts were underway for from Turkovac use abroad in other countries also but Azerbaijan was the first country to complete preparations for trials. He said the vaccine would be available for any elderly citizen of Azerbaijan of 18 and 59 who received two doses of an inactive vaccine (including last dose was administered at least 90 days ago) and those who were not infected with COVID-19 earlier.
Turkovac has attracted enormous interest from the Turks public when it was included in the country’s vaccination program last year. the program that started in January 2021, also includes CoronaVac, another inactive vaccine developed by the Chinese Sinovac, and a messenger RNA (mRNA) vaccine developed by Pfizer-BioNTech. Authorities hope that the local-made jab will boost the program. Since January 2021, more over 146 millions doses were administered with mass inoculation drive while the number of people who had their three doses of vaccine exceeded 27.3 millions.
Vaccination is considered essential to break the cycle of infections in the pandemic, which has reached new tops last months before drastically decreasing in the past a few weeks. The number of daily cases, which broke a record with over 100,000 in February, is back to about 30,000 nowadays. On Monday, the country reported 34,343 cases.
After reporting high numbers last yearAzerbaijan also managed to limit the number of cases, which was only 149 as of Monday, with 13 dead. According to official figures from the Azerbaijani Ministry of Health, more over 13 millions doses were administered in the country against the coronavirus while more more than 2.8 millions doses were given as a booster.
Turkey first domestically-developed the Turkovac coronavirus vaccine took another cue step. The Ministry of Health announced Tuesday that the blow would be the country first vaccine to be used abroad in its clinical trials in Azerbaijan. Trials of phase III of the vaccine, which received emergency approval in Turkey sooner, will available for citizens of Azerbaijan as a third dose of the vaccine as part of of his trials. Any citizen of the country, which is one of Turkey’s closest allies, who received two doses of another inactive vaccine, will be eligible to participate in the trial.
The ministry said in a statement that the trial will proceed in Cooperation with Baku Health Center Hospital in Azerbaijan in the Azerbaijani capital and the presidency of Health institutes of Turkey (TÜSEB), the main sponsor of from Turkovac development by a group of scientists from the University of Erciyes. A delegation from TÜSEB, including its director professor Erhan Akdogan, professor Ates Kara, who lead turkey main vaccine institute and is a member of the Scientific Advisory Board on Coronavirus of the Ministry of Health, were to travel to Baku to sign a protocol for trials on Wednesday.
The statement also said efforts were underway for from Turkovac use abroad in other countries also but Azerbaijan was the first country to complete preparations for trials. He said the vaccine would be available for any elderly citizen of Azerbaijan of 18 and 59 who received two doses of an inactive vaccine (including last dose was administered at least 90 days ago) and those who were not infected with COVID-19 earlier.
Turkovac has attracted enormous interest from the Turks public when it was included in the country’s vaccination program last year. the program that started in January 2021, also includes CoronaVac, another inactive vaccine developed by the Chinese Sinovac, and a messenger RNA (mRNA) vaccine developed by Pfizer-BioNTech. Authorities hope that the local-made jab will boost the program. Since January 2021, more over 146 millions doses were administered with mass inoculation drive while the number of people who had their three doses of vaccine exceeded 27.3 millions.
Vaccination is considered essential to break the cycle of infections in the pandemic, which has reached new tops last months before drastically decreasing in the past a few weeks. The number of daily cases, which broke a record with over 100,000 in February, is back to about 30,000 nowadays. On Monday, the country reported 34,343 cases.
After reporting high numbers last yearAzerbaijan also managed to limit the number of cases, which was only 149 as of Monday, with 13 dead. According to official figures from the Azerbaijani Ministry of Health, more over 13 millions doses were administered in the country against the coronavirus while more more than 2.8 millions doses were given as a booster.